1 / 20

U.S. Food and Drug Administration

U.S. Food and Drug Administration. Notice: Archived Document The content in this document is provided on the FDA’s website for reference purposes only. It was current when produced, but is no longer maintained and may be outdated. . Regulatory Background . Grant Williams, M.D.

awentia
Télécharger la présentation

U.S. Food and Drug Administration

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. U.S. Food and Drug Administration Notice: Archived Document The content in this document is provided on the FDA’s website for reference purposes only. It was current when produced, but is no longer maintained and may be outdated.

  2. Regulatory Background Grant Williams, M.D. Deputy Director, DODP

  3. Acknowledgements • Planning: NCI, AACR, ASCO • ASCO • Logistics and panelist support • Mary Wilson, Deborah Kamin • FDA • Dianne Spillman

  4. Workshop outline • Background presentations • Regulations and past endpoints • Time to Progression (TTP) • Surrogates and non-inferiority • Question-based discussions • First-line treatment setting • Second and subsequent therapy • Other endpoints • Adjuvant treatment setting • Rectal cancer and neoadjuvant therapy

  5. Outline of Presentation • FDA requirements for new drug approval • Regular approval of cancer drugs: end points used • Accelerated approval of cancer drugs

  6. Requirements for Drug Approval • Safety (FDAC, 1933) • Efficacy demonstrated in adequate and well controlled studies (1962) • Basis for efficacy: • Regular approval • Clinical benefit, or • Established surrogate for clinical benefit • Accelerated approval • Surrogate (reasonably likely to predict CB)

  7. How many trials? • Usually more than one trial is needed. Substantial evidence: “Adequate and well-controlled investigations” • Sometimes a single trial may suffice. • FDAMA (1997) single trial plus other supportive evidence • 1998 FDA Effectiveness Guidance: • Multicenter trial • Statistically strong evidence • Important clinical benefit • Additional trials not ethical

  8. Oncology Efficacy Supplements Only one additional trial may be needed for closely related indications1: • Advanced cancer and earlier cancer • Different dosing regimens • New combinations of drugs 1http://www.fda.gov/cder/guidance/1397fnl.pdf

  9. Regular Approval Endpoints in Oncology

  10. Clinical Benefit Endpoints Supporting Regular Drug Approval • Survival • Improvement in tumor-related symptoms

  11. Established Surrogates Supporting Regular Approval • Disease-free survival (selected settings) • Complete response rates in some settings (e.g., acute leukemia) • Partial response rate in some settings (e.g., hormonal treatment of breast cancer)

  12. DODP: Endpoints for Approval (1/1/90 - 11/1/02) Approvals not based on Survival: • 73% (48/66) of all approvals • 67% (37/55) excluding accelerated approvals

  13. Tumor-related symptoms • Mitoxantrone -Pain • Bisphosphonates -Skeletal morbidity scale • Daunozome -Visible lesions of KS • Photofrin -Dysphagia scale

  14. Accelerated approval • Serious or life-threatening disease • Drug must provide benefit over available therapy • Surrogate endpoint may be used • Surrogate endpoint must be reasonably likely to predict clinical benefit • Post marketing studies must verify clinical benefit

  15. Evidence for Accelerated Approval • Substantial evidence from well controlled clinical trials regarding a surrogate endpoint • NOT: Borderline evidence regarding a clinical benefit endpoint

  16. Single Arm Trials (SAT) and Accelerated approval (AA) • SAT require few patients • SAT for AA limit study to refractory disease • SAT have limited ability to evaluate valuable endpoints such as TTP, QOL, and Survival

  17. Randomized Trials (RT) and Accelerated approval (AA) • Allows AA at any disease stage (surrogate beats available therapy) • Allows “add-on” design (A vs A + B) • Allows a variety of endpoints • Defines individual drug contribution • (oxaliplatin vs 5FU/LCV versus oxaliplatin + 5FU/LCV)

  18. ODAC Meeting on: Accelerated Approvals(March 2003) • 19 NDAs or BLAs for new treatment indications (involving 16 drugs) • Confirmatory studies should be part of drug development plan • Consider interim analysis of surrogate endpoint for AA

  19. Summary of Presentation • FDA requirements • Evidence from Trials or Trial+ • RA: Clinical Benefit or accepted surrogate • AA: Advantage over available therapy with regard to a “reasonably likely surrogate” • Cancer Approvals • Important question: • Should TTP be considered an accepted surrogate in any colon cancer setting?

More Related